News | May 10, 2016

Imricor Enrolls First Patients in Study of Vision-MR Ablation Catheter

Study of 35 patients will evaluate device for treatment of atrial flutter under real-time MRI guidance

Imricor, Vision-MR ablation catheter, clinical study, MRI guidance

May 10, 2016 — Imricor Medical Systems announced enrollment of the first patients in a clinical study to evaluate the Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance. The study is sponsored by the Leipzig Heart Center in Leipzig, Germany. Professor Gerhard Hindricks M.D., head of the Department of Electrophysiology at the heart center, is the principal investigator. This single-center study will enroll up to 35 patients.

"We truly believe that ablating in the MRI adds substantial benefits to our standard procedures," said Hindricks. "For example, during one procedure, we were able to visualize with MR an abnormality in the patient's heart and modify our catheter placement to successfully complete the ablation. In a traditional lab, this would have been a 'difficult' procedure and we would not have known why, but with MR, we were able to see the anatomical challenges and tailor the ablation. This is quite exciting."

Imricor's Vision-MR catheter, when used with the Advantage-MR EP Recorder/Stimulator System, allows physicians to perform cardiac ablations under MRI guidance. With real-time MRI, physicians can individualize the ablation for each patient's unique cardiac structure and substrate. In addition, they can assess lesion quality and fill gaps in ablation lines during the initial procedure. Ablations guided by MRI have the potential to improve outcomes and provide safer, more cost-effective treatment – all in an environment that is free of radiation for both the patient and physician.

For more information: www.imricor.com


Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now